Know Cancer

forgot password

A Phase II Study of MK-2206 in Patients With Advanced Hepatocellular Carcinoma Who Have Failed or Are Intolerant of One Prior Line of Anti-Angiogenic Therapy

Phase 2
18 Years
Open (Enrolling)
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer

Thank you

Trial Information

A Phase II Study of MK-2206 in Patients With Advanced Hepatocellular Carcinoma Who Have Failed or Are Intolerant of One Prior Line of Anti-Angiogenic Therapy


I. Evaluate the median progression-free survival in patients with advanced hepatocellular
carcinoma treated with MK-2206 after failure of one prior line of anti-angiogenic therapy.


I. Evaluate the objective response rate (CR + PR). II. Evaluate the median overall survival.
III. Evaluate the tolerability and toxicity profile of MK-2206 in this patient population.

IV. Explore, in a preliminary fashion, potential molecular predictors of efficacy.


Patients receive oral Akt inhibitor MK2206 on days 1, 8, 15, and 22. Courses repeat every 28
days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 4 weeks and then every 3-6
months thereafter.

Inclusion Criteria:

- Unresectable or metastatic HCC for which standard curative measures do not exist

- The diagnosis of hepatocellular carcinoma should be based on at least one of the

- The presence of one or more liver lesions, measuring >= 2 cm, with
characteristic arterial enhancement and venous washout in the setting of
liver cirrhosis and/or hepatitis B or C infection

- The presence of liver lesion(s) with AFP >= 400

- Tissue confirmation in the absence of either or both of the above

- Tissue availability is desired and will be sought, but tissue availability
is not mandated for accrual to the study

- Patients must have measurable disease, defined as at least one lesion that can be
accurately measured in at least one dimension, and that has not been the target of
local or regional therapy including transarterial chemoembolization, intra-arterial
chemotherapy, ethanol, or RFA ablation

- One prior line of systemic anti-angiogenic therapy is required; this type of therapy
includes, but is not restricted to, sorafenib, bevacizumab, sunitinib, or brivanib
given as single agents or in combination with other agents

- No clinically evident ascites (minimal, medically controlled ascites detectable on
imaging studies only is allowed)

- No Child-Pugh C cirrhosis or Child-Pugh B cirrhosis with more than 7 points

- No fibrolamellar carcinoma or any mixed variants of HCC with dominant fibrolamellar

- Patients with known brain metastases should be excluded from this clinical trial

- ECOG 0-1

- Life expectancy of greater than 3 months

- Leukocytes >= 3,000/mcL

- Absolute neutrophil count > 1,000 mcL

- Platelets >= 70,000/mcL

- Total bilirubin =< 1.5 institutional upper limit of normal

- AST (SGOT)/ALT (SGPT) < 5 x institutional upper limit of normal

- Creatinine within normal institutional limits OR creatinine clearance >= 60 mL/min

- Serum albumin >= 2.8 g/dL

- Not pregnant or nursing

- Fertile patients must use two forms of contraception (hormonal or barrier method of
birth control; abstinence) prior to study entry and for the duration of study

- Must agree to collection of correlative blood samples during the study

- No patients unable to swallow pills or diagnosed with a gastrointestinal disorder
that is likely to interfere with the absorption of MK-2206 or with the patient's
ability to take regular oral medication

- Patients with hyperglycemia should be well controlled on oral agents before the
patient enters the trial

- Patients with HgbA1C levels >= 8% or fasting blood glucose >= 150 mg/dL are not
eligible for this study

- Baseline QTcF > 450 msec (male) or QTcF> 470 msec (female) will exclude patients from
entry on study

- Patients with hepatitis B infection, defined by a positive hepatitis B surface
antigen test, should be on suppressive anti-viral therapy

- Only the following anti-viral therapies are allowed while a patient is on study:
tenofovir disoproxil fumarate and entecavir

- Patients with hypothyroidism must be on a stable dose of thyroid replacement and
be clinically euthyroid

- No esophageal or gastric variceal bleeding within the last 6 months

- Patients with prior history of variceal bleeding must have had an upper
endoscopy (EGD) with appropriate treatment of varices within 6 months prior to
study entry

- No uncontrolled intercurrent illness including, but not limited to:

- Ongoing or active infection

- Symptomatic congestive heart failure

- Unstable angina pectoris

- Cardiac arrhythmia

- Psychiatric illness/social situations that would limit compliance with study

- None of the following:

- Uncontrolled hypertension (systolic BP > 150 or diastolic BP > 100 on two
occasions within two weeks of beginning therapy on this protocol)

- Myocardial infarction within 6 months

- NYHA class > II

- Clinically significant bradycardia related to underlying cardiac disease

- Clinically significant bundle branch block related to underlying cardiac disease

- No patients with second primary cancer (except adequately treated nonmelanoma skin
cancer, curatively treated in-situ cancer of the cervix, or other solid tumors
including lymphomas without bone marrow involvement curatively treated with no
evidence of disease for ≥ 5 years)

- The exception to this criterion is prostate cancer treated definitively with
surgery and/or radiation with normal PSA and no clinical evidence of residual or
recurrent prostate cancer

- HIV-positive patients on combination antiretroviral therapy are ineligible

- No history of allergic reactions attributed to compounds of similar chemical
orbiologic composition to MK-2206 or other agents used in the study

- No medications that cause QTc interval prolongation

- Any number of prior regional therapies with transarterial chemoembolization,
intra-arterial chemotherapy, or ablative therapy is allowed

- No more than 1 prior line of systemic therapy for advanced and/or unresectable

- No patients who have had anti-angiogenic therapy, chemotherapy, radiotherapy or
regional therapy (such as transarterial chemoembolization, intra-arterial
chemotherapy) within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to
entering the study or those who have not recovered from adverse events due to agents
administered more than 4 weeks earlier

- Localized radiation for palliation (i.e., bony metastasis, etc.) given for < 3
days is allowed before therapy and is not subject to the 4-week waiting

- Local ablative therapy such as radiofrequency ablation or cryotherapy must have
been completed more than 2 weeks prior to study entry

- Patients may not be receiving any other investigational or non-investigational agents
or therapies directed at treating their hepatocellular carcinoma

- Patients may not be receiving any other investigational agents for any condition

- Patients receiving any medications or substances that are inhibitors or inducers of
CYP3A4 are ineligible

Type of Study:


Study Design:

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Progression-free survival

Outcome Time Frame:

Up to 4 weeks

Safety Issue:


Principal Investigator

Anthony El-Khoueiry

Investigator Role:

Principal Investigator

Investigator Affiliation:

Beckman Research Institute


United States: Food and Drug Administration

Study ID:




Start Date:

December 2010

Completion Date:

Related Keywords:

  • Adult Primary Hepatocellular Carcinoma
  • Advanced Adult Primary Liver Cancer
  • Localized Unresectable Adult Primary Liver Cancer
  • Recurrent Adult Primary Liver Cancer
  • Carcinoma
  • Liver Neoplasms
  • Carcinoma, Hepatocellular



Loyola University Medical Center Maywood, Illinois  60153
Ingalls Memorial Hospital Harvey, Illinois  60426
Central Illinois Hematology Oncology Center Springfield, Illinois  62701
City of Hope Medical Center Duarte, California  91010
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center Columbus, Ohio  43210-1240
University of Pittsburgh Pittsburgh, Pennsylvania  15261
Tower Cancer Research Foundation Beverly Hills, California  90211
UC Davis Comprehensive Cancer Center Sacramento, California  95817
Decatur Memorial Hospital Decatur, Illinois  62526
University of Chicago Comprehensive Cancer Center Chicago, Illinois  60637-1470
Northern Indiana Cancer Research Consortium South Bend, Indiana  
Penn State Milton S Hershey Medical Center Hershey, Pennsylvania  17033
Froedtert and the Medical College of Wisconsin Milwaukee, Wisconsin  53226
Evanston CCOP-NorthShore University HealthSystem Evanston, Illinois  60201
Joliet Oncology-Hematology Associates Limited Joliet, Illinois  60435
Illinois CancerCare-Peoria Peoria, Illinois  61615
Fort Wayne Medical Oncology and Hematology Inc - State Boulevard Fort Wayne, Indiana  46845
Saint John's Mercy Medical Center Saint Louis, Missouri  63141
University of Maryland Greenebaum Cancer Center Baltimore, Maryland  21201
Oncology Care Associates PLLC St. Joseph, Michigan  49085
University of Michigan University Hospital Ann Arbor, Michigan  48109
Southern Illinois University Springfield, Illinois  62702